2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-129340
    AS-183 147317-12-2 98%
    AS-183 is an inhibitor of cholesterol acyltransferase (ACAT) (IC50=0.94 µM). AS-183 also inhibits the formation of cholesterol esters in HepG2, CaCo2 and THP-1 cells with IC50 values ​​of 18.1, 25.5 and 34.5 µM, respectively. AS-183 can be used in the study of atherosclerosis and hypercholesterolemia.
    AS-183
  • HY-129406
    AF 698 82958-11-0 98%
    AF 698 is a phthalate derivative of Apovincamine (HY-135743) that can be used as a peripheral vasodilator with selective vasomotor effects on cerebral microvascular circulation. AF 698 has better vasodilator effect than Vincamine (HY-B1021), but there is no significant difference in the protective effect of the two drugs against hypobaric hypoxia-induced lethality in mice.
    AF 698
  • HY-129412
    A-74273 130316-95-9 98%
    A-74273 is an orally active peptide renin inhibitor (IC50=3.1 nM). A-74273 competitively binds to the active site of renin, preventing angiotensinogen from being converted to ANG-I, thereby reducing the level of angiotensin II. A-74273 can be used in the study of diseases such as hypertension.
    A-74273
  • HY-129427
    DC-015 149847-87-0 98%
    DC-015 is a selective and orally active alpha 1-adrenoceptor antagonist on plasma lipid and vascular reactivity in hyperlipidaemic rodent model. DC-015 is a synthesized quinazoline derivative. DC-015 decreases mean arterial pressure in rats. DC-015 has antihypertensive activity.
    DC-015
  • HY-129436
    (S)-Bucindolol 91548-61-7 98%
    (S)-Bucindolol is the (S)-isomer of Bucindolol (HY-103214), a β1-adrenergic receptor blocker. (S)-Bucindolol can be utilized in research on cardiac failure.
    (S)-Bucindolol
  • HY-129458
    Cerivastatin 145599-86-6 98%
    Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels. Cerivastatin also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect.
    Cerivastatin
  • HY-129500
    Zofenoprilat arginine 81872-09-5 98%
    Zofenoprilat arginine is an antihypertensive agent that enhances the effect of bradykinin on coronary flow, particularly in the presence of sulfhydryl-containing converting enzyme inhibitors.
    Zofenoprilat arginine
  • HY-129599
    L-2286 684276-17-3 98%
    L-2286 is an orally active PARP-1 inhibitor. L-2286 alleviates carotid artery remodeling, oxidative stress and inflammation in spontaneously hypertensive rats, protects neurons in the dorsal hippocampus, and reduces pyramidal cell loss and gliosis without affecting blood pressure. L-2286 can be used in research related to hypertension.
    L-2286
  • HY-129660
    LK 204-545 83068-69-3 98%
    LK 204-545 is a potent and highly selective β1-adrenoceptor antagonist. LK 204-545 is promising for research of cardiovascular diseases.
    LK 204-545
  • HY-129670
    KMUP-1 81996-46-5
    KMUP-1 is a xanthine derivative with vasodilator activity. KMUP-1 is a inhibitor of phosphodiesterase (PDE) and activator of soluble guanylyl cyclase (sGC). KMUP-1 stimulates NO/sGC/cyclic GMP pathway. KMUP-1 has K+ channels opening activity. KMUP-1 ameliorates ischemia-induced cardiomyocyte apoptosis. KMUP-1 can be used for cardiovascular and anti-inflammatory study.
    KMUP-1
  • HY-129695
    PD 132002 134452-04-3 98%
    PD 132002 is an orally active, potent renin inhibitor. PD 132002 weakly inhibits pepsin. PD 132002 produces substantial reductions in blood pressure.
    PD 132002
  • HY-129706
    LY127210 free base 57184-68-6 98%
    LY127210 free base is an orally active peripheral arterial vasodilating antihypertensive agent. LY127210 free base interferes with the baroreflex mechanism, exerts direct myocardial bradycardic activity, has no α or β receptor blocking properties, and acts via all conventional administration routes. LY127210 free base reduces vascular resistance, cardiac output, heart rate, left ventricular end-diastolic pressure, regional vascular resistance, as well as blood flow in the skin and cerebral cortex. LY127210 free base can be used in research related to hypertension.
    LY127210 free base
  • HY-129737
    A-62198 117978-26-4 98%
    A-62198 is a potent and selective renin inhibitor with antihypertensive activity. A-62198 reduces mean arterial pressure (MAP) in anesthetized, salt-deprived monkeys in a dose-dependent manner. A-62198 induced MAP reduction in normal monkeys that reached statistical significance at the highest dose and significantly inhibited plasma renin activity (PRA) at all doses.
    A-62198
  • HY-129782
    SC-55858 179464-49-4 98%
    SC-55858 is an effective superoxide dismutase simulator. SC-55858 increased heart rate and decreased mean arterial pressure and left ventricular systolic and end-diastolic pressures in conscious dogs.
    SC-55858
  • HY-129786
    LG 82-4-00 91505-18-9 98%
    LG 82-4-00 is a thromboxane (TX) synthase inhibitor with an IC50 value of 1.1 μM. LG 82-4-00 can inhibit collagen-induced TXB2 formation and platelet aggregation in plasma. LG 82-4-00 can be used in studies related to thrombotic diseases.
    LG 82-4-00
  • HY-129808
    VPC12249 403520-23-0 98%
    VPC12249 is a competitive dual LPA1/LPA3 antagonist with Ki values of 137nM and 428 nM, respectively. VPC12249 inhibits calcium mobilization in HEK293T cells with a Ki value of ~130 nM. VPC12249 is promising for research of ovarian cancer and hypertensive diseases.
    VPC12249
  • HY-129831
    Prostaglandin I3 sodium 68324-96-9 98%
    Prostaglandin I3 sodium is an inhibitor of platelet aggregation with vasodilatory effects.
    Prostaglandin I3 sodium
  • HY-129955
    Carbazochrome salicylate 13051-01-9 98%
    Carbazochrome salicylate is a capillary stabiliser and used for the research of haemorrhage. Carbazochrome salicylate is an antihemorrhagic agent.
    Carbazochrome salicylate
  • HY-130064
    Omega-3 acid ethyl esters 861006-80-6 98%
    Omega-3 acid ethyl esters (P-OM3) is a omega-3 polyunsaturated fatty acid. Omega-3 acid ethyl esters can be used for the researches of severe hypertriglyceridemia and cardiovascular diseases.
    Omega-3 acid ethyl esters
  • HY-130071
    Iproplatin 62928-11-4 98%
    Iproplatin (CHIP) is an anti-cancer agent with reduced toxicity in testicular and ovarian cancers. The major reduced product of Iproplatin by glutathione is chloro-bis (isopropylamine) glutathionatoplatinum (II). Iproplatin is promising for research of Thrombocytopenia and a wide range of cancers.
    Iproplatin
Cat. No. Product Name / Synonyms Application Reactivity